

Innovation all for the patients



Roche A member of the Roche group

Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo Nodularis

TOKYO, June 22, 2022 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that [Galderma](#) issued a press release on June 22 regarding positive topline results of a phase III clinical study, in prurigo nodularis (OLYMPIA 2) for the humanized anti-human IL-31 receptor A monoclonal antibody nemolizumab, created by Chugai. Clinical development of nemolizumab outside Japan has been conducted by Galderma.

Please refer to the link below for details of the press release:

Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis

<https://www.galderma.com/news/galderma-announces-positive-data-phase-iii-trial-demonstrating-efficacy-and-safety-nemolizumab>

###